NRG Oncology Executive Director is Stepping Down from the Position

04/29/2022

Kati Stoermer,
Executive Director of NRG Oncology since 2018, has announced that she will be
stepping down from her role effective later in May. Having joined NRG Oncology
during the final preparations for the renewal of the current NCTN grant, her
four plus years tenure has been marked by the successful implementation of that
grant in addition to the successful renewals of the NRG Oncology NCORP Research
Base and Biospecimen Banking Grants. In 2020, her leadership allowed the
organization to continue with little pause as the pandemic took hold. A major
focus of her role in adapting to the pandemic-induced changes has been leading
the revisioning and execution of the semiannual NRG Oncology meetings, with the
newest generation of hybrid NRG meetings planned for this summer. Other
hallmarks of her leadership have been the formation of a Veterans
Affairs/Military Treatment Facilitate subcommittee to help those populations
engage in more NCI-funded clinical trials, admittedly a passion project for the
US Navy veteran.

“Kati’s
departure will leave a hole in our organization, and we are sorry to see her
go,” noted Norman Wolmark, MD one of NRG’s Group Chairs.

NRG Oncology is
naming Sharon Hartson Stine as Interim Executive Director effective May 2,
2022. “We are pleased that Sharon is able to assume the role of interim
executive director while we evaluate the group’s current requirements in order
to ensure NRG’s success as we embark on this new chapter,” said Robert Mannel,
MD, an NRG Group Chair. Hartson Stine currently serves as Senior Director, NRG
Oncology – Philadelphia West Operations Center and has been with the
organization since it formed in 2013 and for many years prior to that with the
RTOG.

Stoermer will
stay on to support the transition through May 20, 2022.